Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269101 | 0.93 | KCNH2 (0.36) | SIGMAR1KCNH2SCN5ASCN9AALK | |
| SCHEMBL31268817 | 0.90 | KCNH2 (0.38) | KCNH2SCN5ASCN9ACNR1CNR2 | |
| SCHEMBL30983467 | 0.89 | PDE2A (0.38) | SIGMAR1KCNH2SCN5ASCN9AALK | |
| SCHEMBL31269467 | 0.88 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269028 | 0.87 | KCNH2 (0.37) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269090 | 0.87 | HTR6 (0.35) | HTR6KCNH2SCN5ASCN9ACNR1 | |
| SCHEMBL31269213 | 0.87 | PIK3CD (0.36) | HTR6KCNH2SCN5ASCN9AALK | |
| SCHEMBL31268930 | 0.87 | KCNH2 (0.34) | KCNH2SCN5ASCN9ACNR1PIK3CD | |
| SCHEMBL31269411 | 0.86 | KCNH2 (0.34) | KCNH2SCN5ASCN9ACNR1PIK3CD | |
| SCHEMBL31269320 | 0.85 | HTR6 (0.34) | HTR6KCNH2SCN5ASCN9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |